secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001618835-22-000142
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Biosciences appoints Jenny Yip from Adjuvant Capital to board of directors
--------------------------------------------------------------------------------

- Jenny Yip, Managing Partner at Adjuvant Capital, elected to Evofem board effective August 2, 2022.
- Adjuvant Capital previously invested $25 million to fund Phase 3 EVOGUARD trial for Phexxi in chlamydia/gonorrhea prevention.
- Top-line results from EVOGUARD trial expected fall 2022.
- Board expands from five to six independent directors with Yip's appointment.
- Yip's term expires at 2023 annual meeting; standard indemnification agreement entered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000161883522000142/0001618835-22-000142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000161883522000142/evfm-20220802.htm
  HTML page:      https://secwatch.observer/filing/0001618835-22-000142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer